PubRank

Tessa L Holyoake

Author PubWeight™ 113.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002 6.64
3 Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006 4.41
4 Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012 2.96
5 Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007 2.68
6 BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010 2.17
7 Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2011 2.11
8 Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 2007 2.08
9 Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012 2.08
10 Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2006 1.85
11 Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 2013 1.75
12 PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013 1.72
13 Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood 2013 1.70
14 Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002 1.68
15 Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood 2013 1.65
16 Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2007 1.60
17 Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2009 1.50
18 Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006 1.43
19 BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2007 1.40
20 Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010 1.33
21 Punish the parent not the progeny. Blood 2004 1.32
22 Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008 1.30
23 Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006 1.29
24 Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 2007 1.24
25 Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011 1.16
26 Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012 1.16
27 Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013 1.13
28 The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 2014 1.13
29 Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 2007 1.09
30 Evolving molecular therapy for chronic myeloid leukaemia--are we on target? Hematology 2005 1.04
31 BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009 1.02
32 Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. PLoS One 2012 1.01
33 Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica 2011 1.00
34 The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2012 0.99
35 Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 2013 0.99
36 Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 2013 0.98
37 Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007 0.97
38 Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells 2014 0.96
39 Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood 2013 0.95
40 In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep 2011 0.94
41 Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011 0.91
42 A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health 2009 0.91
43 Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep 2010 0.88
44 Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Res 2010 0.88
45 Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev Anticancer Ther 2012 0.87
46 HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis 2006 0.87
47 Role of autophagy in cancer prevention, development and therapy. Essays Biochem 2013 0.86
48 Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009 0.86
49 Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood 2008 0.86
50 The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol 2007 0.86
51 BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Br J Haematol 2012 0.85
52 Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy. J Control Release 2010 0.84
53 Retracted FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. Blood 2009 0.84
54 Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data. Blood Rev 2010 0.84
55 Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. J Exp Med 2011 0.83
56 Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin North Am 2011 0.83
57 Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Exp Hematol 2005 0.82
58 Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 2010 0.82
59 Targeted therapy in haematological malignancies. J Pathol 2010 0.82
60 Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. Proteomics 2013 0.81
61 Redirecting traffic using the XPO1 police. Blood 2013 0.80
62 Stem cells in chronic myeloid leukaemia. Cancer Biomark 2007 0.80
63 Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol 2008 0.80
64 Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003 0.80
65 Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets 2013 0.80
66 Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. Br J Haematol 2005 0.79
67 Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 2005 0.79
68 A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Mol Cell Proteomics 2013 0.79
69 Can we afford to let sleeping dogs lie? Blood 2005 0.79
70 Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood 2012 0.78
71 Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Rev Hematol 2011 0.77
72 Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Res 2010 0.77
73 Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest 2014 0.77
74 Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Exp Hematol 2009 0.77
75 Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol 2013 0.76
76 Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003 0.75
77 Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clin Infect Dis 2004 0.75
78 Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology 2003 0.75
79 Stem Cell Guardians - Old and New Perspectives in LSC Biology. Curr Drug Targets 2017 0.75
80 Investigation into omacetaxine solution stability for in vitro study. Biomed Chromatogr 2011 0.75
81 Fluorescence in situ hybridization for BCR-ABL. Methods Mol Med 2004 0.75
82 BCR-ABL FISH monitoring of CML: a survey of current UK practice. Br J Haematol 2002 0.75
83 High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica 2007 0.75